Abstract
Uterine epithelial cancers are the most common type of gynecologic cancer in the United States. The American Cancer Society estimated 53,000 new cases of uterine cancers in 2014 with 8,600 deaths from advanced or recurrent cases, 99% of which are endometrial cancer. The 5-year survival rate of low-stage, low-grade endometrioid adenocarcinoma is greater than 90%. In contrast, advanced stage endometrioid adenocarcinomas and Type II (serous and carcinosarcoma) endometrial cancers have a much poorer prognosis, with the 5-year survival rate of advanced stage uterine carcinosarcoma as low as 9%. Together, these endometrial cancers with poor prognoses comprise almost half of all cases in the US, creating a significant medical obstacle for management. The authors present a review of endometrial cancer pathology, diagnosis and treatment. Included on the topic of treatment are: surgery, endocrine therapy, and chemotherapy with commentary on pertinent phase II and III clinical trials. The discussion covers single and multi-agent chemotherapy. Also covered are current clinical trials using targeted therapies such as mTOR inhibitors, angiokinase inhibitors, and HER2-directed agents. The review concludes with thoughts on future directions in therapeutic management of this disease.
Keywords: Endometrial cancer, endometrioid adenocarcinoma, serous, carcinosarcoma, chemotherapy, endocrine therapy, targeted therapy.
Current Cancer Therapy Reviews
Title:Treatment of Uterine Carcinomas
Volume: 11 Issue: 4
Author(s): Mary Chu, Estrelania Williams, D. Stave Kohtz, Tamara Kalir and David Fishman
Affiliation:
Keywords: Endometrial cancer, endometrioid adenocarcinoma, serous, carcinosarcoma, chemotherapy, endocrine therapy, targeted therapy.
Abstract: Uterine epithelial cancers are the most common type of gynecologic cancer in the United States. The American Cancer Society estimated 53,000 new cases of uterine cancers in 2014 with 8,600 deaths from advanced or recurrent cases, 99% of which are endometrial cancer. The 5-year survival rate of low-stage, low-grade endometrioid adenocarcinoma is greater than 90%. In contrast, advanced stage endometrioid adenocarcinomas and Type II (serous and carcinosarcoma) endometrial cancers have a much poorer prognosis, with the 5-year survival rate of advanced stage uterine carcinosarcoma as low as 9%. Together, these endometrial cancers with poor prognoses comprise almost half of all cases in the US, creating a significant medical obstacle for management. The authors present a review of endometrial cancer pathology, diagnosis and treatment. Included on the topic of treatment are: surgery, endocrine therapy, and chemotherapy with commentary on pertinent phase II and III clinical trials. The discussion covers single and multi-agent chemotherapy. Also covered are current clinical trials using targeted therapies such as mTOR inhibitors, angiokinase inhibitors, and HER2-directed agents. The review concludes with thoughts on future directions in therapeutic management of this disease.
Export Options
About this article
Cite this article as:
Chu Mary, Williams Estrelania, Stave Kohtz D., Kalir Tamara and Fishman David, Treatment of Uterine Carcinomas, Current Cancer Therapy Reviews 2015; 11 (4) . https://dx.doi.org/10.2174/1573394712666151119213759
DOI https://dx.doi.org/10.2174/1573394712666151119213759 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Histone Deacetylase Inhibitors: Recent Insights from Basic to Clinical Knowledge & Patenting of Anti-Cancer Actions
Recent Patents on Anti-Cancer Drug Discovery Allelic Variations in 5, 10-Methylenetetrahydrofolate Reductase Gene and Susceptibility to Cervical Cancer in Indian Women
Drug Metabolism Letters Prolyl-Specific Peptidases and Their Inhibitors in Biological Processes
Current Chemical Biology CDC25A and B Dual-Specificity Phosphatase Inhibitors: Potential Agents for Cancer Therapy
Current Medicinal Chemistry The Immunoregulatory Activity of Mesenchymal Stem Cells: ‘State of Art’ and ‘Future Avenues’
Current Medicinal Chemistry Pharmacogenetics of Estrogen Metabolism and Transport in Relation to Cancer
Current Drug Metabolism Hypomethylation and Activation of Syncytin-1 Gene in Endometriotic Tissue
Current Pharmaceutical Design Molecular Bases of Liver Cancer Refractoriness to Pharmacological Treatment
Current Medicinal Chemistry Recent Knowledge and New Pharmaceutical Products in Potential Alleviation of Endometriosis
Recent Patents on Inflammation & Allergy Drug Discovery Targeting Tumors Using Estrogen Receptor Ligand Conjugates
Current Cancer Drug Targets Cyclooxygenases Regulation by Estradiol on Endothelium
Current Pharmaceutical Design Network Propagation Reveals Novel Features Predicting Drug Response of Cancer Cell Lines
Current Bioinformatics Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
Recent Patents on Anti-Cancer Drug Discovery Tumor-related Molecular Regulatory Mechanisms of Long Non-coding RNA RMST: Recent Evidence
Mini-Reviews in Medicinal Chemistry Curcumin Therapeutic Modulation of the Wnt Signaling Pathway
Current Pharmaceutical Biotechnology Relevance of Aromatase Inhibitors in Breast Cancer Treatment
Current Topics in Medicinal Chemistry Molecular and Biological Functions of Melatonin in Endometrial Cancer
Current Drug Targets How to Inhibit Telomerase Activity for Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Lapatinib as a Chemotherapeutic Drug
Recent Patents on Anti-Cancer Drug Discovery Radioiodinated Ginger Compounds (6-gingerol and 6-shogaol) and Incorporation Assays on Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry